PERSONAL INFORMATION
Name: ZHANG Yan
Gender: Female
CONTACT INFORMATION
Email: yanzhang@cqmu.edu.cn
Address: Yixueyuan Road, Yu Zhong District, Chongqing, 400016, China
EDUCATION EXPERIENCE
1987.9-1992.7, BM，Medical laboratory，Chongqing Medical University.
1994.9-1997.7, PhD，Clinical Laboratory Diagnostics，Chongqing Medical University.
1999.3-1999.5, School of Medicine, University of Hong Kong.
2005.1-2005.12, Shanghai Academy of Biological Sciences, Chinese Academy of Sciences.
2011.10-2012.9, MD Anderson Cancer Center, University of Texas.
WORKING EXPERIENCE
1992.7-1997.9, Teaching Assistant, Department of Laboratory Medicine, Chongqing Medical University.
1997.10-2002.9, Lecturer, Department of Laboratory Medicine, Chongqing Medical University.
2002.10-2011.9, Associate Professor, School of Laboratory Medicine, Chongqing Medical University.
2011.10-now, Professor, School of Laboratory Medicine, Chongqing Medical University.
RESEARCH INTERESTS
Professor ZHANG is committed to understanding the interaction mechanism between the tumor cells and the stromal cells, aiming to explore the molecular mechanism of tumor development and search for new treatment strategies for breast cancer and cervical cancer. Starting with BMP9, a secretory protein that is abnormally under-expressed in breast cancer, she found that exogenous BMP9 can inhibit the malignant progression and bone metastasis of breast cancer. In addition, the roles of ICAT as an activator in cervical cancer were also intensively investigated. Professor ZHANG has undertaken 6 National Natural Science Foundation projects and 3 Science and Technology Research Projects of the Chongqing Basic Research and Education Commission.
HONOUR & AWARDS
1.Outstanding Communist Party Member
2.Excellent Award for Teaching and Education
3.Candidates for the second level of Chongqing's "322 Key Talent Project"
4.Outstanding young and middle-aged teachers in universities in Chongqing
5.Reserve candidates for the second academic and technological leaders in Chongqing
PUBLICATIONS
1.Hu J, Liao D, Sun Z, Ren W, Zhao L, Fang Y, Hu K, Yu H, Liu S, Zhou L, He T, Zhang Y*. The HPV16 E6, E7/miR-23b-3p/ICAT signaling axis promotes proliferation, migration, invasion and EMT of cervical cancer cells. Carcinogenesis, 2023, 44(3):221-231.
2.Kai Hu, Huomei Yu, Shiyan Liu, Deyu Liao and Yan Zhang*. Systematic pan-cancer analysis on the expression and role of regulator of chromatin condensation 1/small nucleolar RNA host gene 3/small nucleolar RNA host gene 12. Frontiers in Molecular Biosciences, 2022, 9.
3.Zijiu Sun, Jing Hu, Wei Ren, Yuting Fang, Kai Hu, Huomei Yu, Deyu Liao，Shiyan Liu, Lan Zhou, Tongchuan He, Yan Zhang*. LncRNA SNHG3 regulates the BMSC osteogenic differentiation in bone metastasis of breast cancer by modulating the miR-1273g-3p/BMP3 axis. BIOCHEM BIOPH RES CO, 2022, 594:117-123.
4.QunWan, MinTang, Shilei Sun, Jing Hu, Zijiu Sun, Yuting Fang, Tongchuan He, Yan Zhang*. SNHG3 promotes migration, invasion, and epithelial-mesenchymal transition of breast cancer cells through the miR-186-5p/ZEB1 axis. Am J Transl Res, 2021,13(2):585-600.
5.Gou L, Liu M, Xia J, Wan Q, Jiang Y, Sun S, Tang M, Zhou L, He T, Zhang Y*. BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1. Int J Mol Sci, 2018, 19(4):1116.
6.Liu M, Gou L, Xia J, Wan Q, Jiang Y, Sun S, Tang M, He T, Zhang Y*. LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2. Int J Mol Sci, 2018, 19(7):1866.
7.Wang T, Zhang Z, Wang K, Wang J, Jiang Y, Xia J, Gou L, Liu M, Zhou L, He T, Zhang Y*. Inhibitory effects of BMP9 on breast cancer cells by regulating their interaction with pre-adipocytes/adipocytes. Oncotarget, 2017, 8(22):35890-35901.
8.Wang K, Sun X, Feng HL, Fei C, Zhang Y*. DNALK2 inhibits the proliferation and invasiveness of breast cancer MDA-MB-231 cells through the Smad-dependent pathway. Oncol Rep, 2017, 37(2):879-886.
9.Jiang Y, Ren W, Wang W, Xia J, Gou L, Liu M, Wan Q, Zhou L, Weng Y, He T, Zhang Y*. Inhibitor of β-catenin and TCF (ICAT) promotes cervical cancer growth and metastasis by disrupting E-cadherin/β-catenin complex. Oncol Rep, 2017, 38(5):2597-2606.
10.Wang W, Weng Y, Ren W, Zhang Z, Wang T, Wang J, Jiang Y, Chen Y, Zhou L, He T, Zhang Y*. Biological roles of human bone morphogenetic protein 9 in the bone microenvironment of human breast cancer MDA-MB-231 cells. Am J Transl Res, 2015, 7(9):1660-1674.
11.Ren W, Sun X, Wang K, Feng H, Liu Y, Fei C, Wan S, Wang W, Luo J, Shi Q, Tang M, Zuo G, Weng Y, He T, Zhang Y*. BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol Biol Rep, 2014, 41(3):1373-1383
12.Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, Zhang Z, Wang T, Wang J, Zhou L, Weng Y, He T, Zhang Y*. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One, 2014, 9(5):e96816.
13.Wang K, Feng H, Ren W, Sun X, Luo J, Tang M, Zhou L, Weng Y, He TC, Zhang Y*. BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin Oncol, 2011, 137(11):1687-1696.
14.Yong-qiang Wang, Ting-mei Chen, Yan Lei, Hong-lei Feng, Ke Wang, Yan zhang*. CGI-100 specific shRNA inhibits proliferation and induces differentiation in leukemia K562 cells. Chinese Journal of Cancer Research,2010，22（2）：126-134.
15.Yan Lei, Yan Zhang*, Ting-mei Chen, Yong-qiang Wang. Effect on proliferation and erythroid differentiation of K562 cells by IER3IP1-knockdown. Chinese Journal of Cancer Research，2009，21（3）：163-170.
